Kamada Reports Record Revenue and EBITDA Growth in Q2 2026
Kamada Ltd (NASDAQ: KMDA) reported record revenue of $54.9 million for the second quarter, a 23% increase driven by strong sales of its proprietary plasma-derived products like KEDRAB and increased demand for VARIZIG and HEPAGAM in the U.S. The company also achieved adjusted EBITDA of $14.1 million with a margin of 26%, up from $10.9 million in Q2 2025, reflecting improved operational efficiency. First-half revenue reached $100.2 million, and Kamada reiterated its full-year guidance for revenue between $200 million to $205 million. Kamada signed a three-year plasma supply agreement worth up to $50 million with an unnamed biopharmaceutical company and plans biosimilar product launches in Q3 2026, targeting annual sales of $15–$20 million within four to five years. The CEO highlighted increased utilization of KEDRAB and the opening of a new FDA-approved RFFIT lab for faster response times.
Tickers: $KMDA
Topics: adjusted_ebitda guidance net_income revenue